Omnicell (OMCL) Cash & Equivalents (2010 - 2026)

Omnicell (OMCL) has reported Cash & Equivalents for 17 consecutive years, with $292.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 26.77% year-over-year to $292.2 million in Q2 2026; TTM through Jun 2026 was $292.2 million, a 26.77% decrease from a year earlier, with the FY2025 full-year figure at $196.5 million, down 46.77% from the prior year.
• Cash & Equivalents was $292.2 million for Q2 2026 at Omnicell, up from $239.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $570.6 million in Q3 2024 and troughed at $180.1 million in Q3 2025.
• A 5-year average of $359.1 million and a median of $354.8 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents surged 67.73% in 2023 and slumped 68.44% in 2025, its largest moves.
• Over 5 years, Cash & Equivalents stood at $330.4 million in 2022, then soared by 41.65% to $468.0 million in 2023, then dropped by 21.11% to $369.2 million in 2024, then plunged by 46.77% to $196.5 million in 2025, then surged by 48.69% to $292.2 million in 2026.
• The last three Cash & Equivalents figures came in at $292.2 million (Q2 2026), $239.2 million (Q1 2026), and $196.5 million (Q4 2025), per Business Quant data.